A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (202200050434)

  • STATUS
    Recruiting
  • End date
    Dec 23, 2025
  • participants needed
    90
  • sponsor
    Mirati Therapeutics Inc.
Updated on 23 November 2022
KRAS
pembrolizumab

Summary

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation

Description


Details
Condition Advanced NSCLC, Metastatic Lung Cancer
Treatment Pembrolizumab, Adagrasib in combination with pembrolizumab
Clinical Study IdentifierNCT05609578
SponsorMirati Therapeutics Inc.
Last Modified on23 November 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed diagnosis of unresectable or metastatic NSCLC (squamous or nonsquamous) with KRAS G12C mutation and PD-L1 TPS ≥ 1%

Exclusion Criteria

Prior systemic treatment for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy (CIT), or any therapy targeting KRAS G12C mutation (eg, sotorasib)
Active brain metastases
Radiation to the lung ≥ 30 Gy within 6 months prior to first dose of study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note